Home > Oncology > New cancer immunotherapy fails in first Roche trial

New cancer immunotherapy fails in first Roche trial


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Reuters - 30/03/2022 - A highly anticipated new cancer immunotherapy by Roche failed to slow the progression of an aggressive form of lung cancer, the Swiss drug maker said on Wednesday, boding ill for a range of rival drug developers working on similar compounds.  The Skyscraper 2 trial was the first to produce results in the final stage of clinical testing in a class of drugs known as anti-TIGIT, which Roche and its U.S. unit Genentech have pioneered.  Roche said it would continue the trial programme for the drug, known as tiragolumab, against various other cancer types.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on